Psychosis



Reducing the Duration of Untreated Psychosis in the United States


Conditions:   First Episode Psychosis (FEP);   At Risk Mental State (ARMS)
Intervention:  
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute of Mental Health (NIMH)
Not yet recruiting


Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis


Condition:   Dementia-related Psychosis
Interventions:   Drug: Placebo;   Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg
Sponsor:   ACADIA Pharmaceuticals Inc.
Recruiting


Occupational Recovery After First Episode Psychosis


Condition:   Psychosis
Intervention:   Behavioral: IPS
Sponsors:   Fraser Health;   BC Ministry of Social Development and Social Innovation;   Canadian Mental Health Association
Recruiting


Using Mobile Technology to Enhance Early Psychosis Treatment Delivery


Conditions:   Psychosis;   Clinical High Risk for Psychosis
Intervention:   Other: Mobile health application - Ginger.io
Sponsors:   University of California, Davis;   Ginger.io
Completed


Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings


Conditions:   Psychosis;   Clinical High Risk for Psychosis
Intervention:   Other: Mobi mHealth app
Sponsor:   University of California, Davis
Completed


Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States


Conditions:   Psychosis;   Remission
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting


Early Intervention Psychosis Communication and Engagement Trial


Condition:   First Episode Psychosis
Interventions:   Other: Digital communication;   Other: Non digital
Sponsor:   South London and Maudsley NHS Foundation Trust
Recruiting


IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2


Conditions:   Psychosis;   Autoimmune Encephalitis
Interventions:   Drug: Intravenous immunoglobulin;   Drug: Placebo;   Drug: Rituximab
Sponsors:   University of Cambridge;   University of Oxford
Not yet recruiting


The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study


Condition:   Parkinson Disease Psychosis
Intervention:   Other: Real-world, non-interventional
Sponsor:   ACADIA Pharmaceuticals Inc.
Recruiting


Reducing the Duration of Untreated Psychosis


Condition:   First Episode Psychosis
Intervention:   Other: Community Campaign La CLAVE
Sponsors:   University of Southern California;   University of California, Los Angeles;   National Institute of Mental Health (NIMH)
Recruiting


Is Cognitive Training Neuroprotective in Early Psychosis?


Conditions:   Psychosis;   Healthy
Interventions:   Device: Magnetic Resonance Imaging;   Behavioral: Treatment as Usual;   Behavioral: Targeted Cognitive Training;   Other: Healthy Controls
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institutes of Health (NIH)
Recruiting


A Study of MP-101 in the Treatment of Psychosis in Alzheimer's Disease


Conditions:   Psychosis;   Alzheimer Disease
Interventions:   Drug: MP-101;   Drug: Placebo
Sponsor:   Mediti Pharma Inc.
Recruiting


A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis


Condition:   Parkinson Disease Psychosis
Interventions:   Drug: SEP-363856;   Drug: Placebo capsule
Sponsor:   Sunovion
Recruiting


COllaborative Shared Care to IMprove Psychosis Outcome


Condition:   Psychosis
Intervention:   Behavioral: Collaborative shared care
Sponsor:   University of Ibadan
Completed


Expanded Access of Pimavanserin for Patients With PD Psychosis


Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate
Sponsor:   ACADIA Pharmaceuticals Inc.
Approved for marketing


Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe


Condition:   Ultra High Risk for Psychosis
Interventions:   Drug: Omega-3 fatty acids;   Other: Placebo
Sponsor:   Rene Kahn
Recruiting


CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes


Conditions:   Insomnia;   Psychosis
Interventions:   Behavioral: Cognitive Behavioral Therapy-Insomnia;   Behavioral: Health and Wellness
Sponsors:   VA Office of Research and Development;   VA Maryland Health Care System
Not yet recruiting


Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis


Condition:   Psychosis
Interventions:   Behavioral: CLUES;   Behavioral: therapy and computer games
Sponsors:   Beth Israel Deaconess Medical Center;   National Institute of Mental Health (NIMH)
Recruiting


A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis


Condition:   Psychosis
Interventions:   Behavioral: Cognitive Adaptation Training;   Behavioral: Action Based Cognitive Remediation
Sponsor:   Centre for Addiction and Mental Health
Active, not recruiting


Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis


Condition:   Psychosis
Intervention:   Device: tDCS
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting


Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis


Condition:   Clinical High Risk for Psychosis
Interventions:   Drug: Aspirin;   Drug: Placebo
Sponsor:   Yale University
Recruiting


First Episode Psychosis and Pathway to Care in Nordland


Condition:   First Episode Psychosis
Intervention:  
Sponsor:   Nordlandssykehuset HF
Active, not recruiting


N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis


Condition:   Schizophrenic Psychoses
Interventions:   Drug: n-acetylcysteine;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Center de Neurosciences Psychiatrique, Lausanne, Switzerland
Completed


A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis


Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate (ACP-103)
Sponsor:   ACADIA Pharmaceuticals Inc.
Active, not recruiting


A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis


Condition:   Parkinson's Disease Psychosis
Interventions:   Drug: Pimavanserin tartrate (ACP-103);   Drug: Placebo
Sponsor:   ACADIA Pharmaceuticals Inc.
Completed

Refine Your Search Advanced Search